A Multicenter, Randomized, Double-Blind, Placebo-Controlled Ph2 Trial of Pacibekitug SC Quarterly or Monthly in Patients with Elevated hs-CRP and Chronic Kidney Disease: TRANQUILITY 90-Day Results
SGLT2 inhibitors on the prevention of contrast-induced acute kidney injury in patients with type 2 diabetes after coronary revascularization: a systematic review and meta-analysis